Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produce inactivated polio vaccines (IPV) in Africa. This agreement is designed to enable regional manufacturing of polio vaccines to serve the potential needs of over 40 African countries. This partnership with Sanofi makes Biovac the first African producer of IPV
Today we meet with British CEO Paul Hudson to find out how he plans to build the Sanofi of tomorrow.
In recent trading sessions, the French stock market has shown resilience, with the CAC 40 Index modestly increasing by 0.11%. This uptick reflects cautious optimism among investors following the European Central Bank's decision to cut interest rates for the first time in five years, signaling a potentially more supportive environment for equities. In this context, dividend stocks can be particularly appealing as they offer potential income in addition to price appreciation opportunities...